T32: Predoctoral and Postdoctoral Training Program in Nanotechnology for Cancer Research

项目摘要 纳米技术和医学之间的界面是科学探索和 创造新的和改进的诊断和治疗工具，以检测，治疗，治愈和预防 人类疾病。我们建议建立一个综合的博士前和博士后培训计划 在癌症研究的纳米技术（NTCR），定位在这个接口。它是基于两个父母 R25和T32培训赠款在同一地区。该计划将建立一个独特的国家资源， 癌症生物学基础研究的跨学科和协同计划，工业 合作和癌症医学的转化研究。该计划培养博士前和 博士后研究员接受跨学科培训，为技术奠定基础， 与目前有限的黑盒输入输出技术相反， 使用，引入新的分子成像模式，开发新的高通量诊断工具， 设计新型药物/抗体/siRNA病毒和非病毒递送系统以治疗人类癌症。NTCR 研究员开发新的癌症诊断，以评估每个病人的预后和最佳的 治疗，基于患者的遗传和表观遗传标记和疾病表型， 为每个患者选择和优化的治疗方法。NTCR学员参加三个 核心课程取决于他们的背景，以及在癌症纳米生物技术的实验室课程。他们 参加期刊俱乐部和专门的年度研讨会，以及临床会议和肿瘤 板. NTCR计划每年将招募具有MD和/或PhD学位的优秀学员 在生物化学，物理学，分子/细胞/癌症生物学，或 工程/物理学科，稳定状态下有2名博士后和6名博士前研究员。的 NTCR计划持续3年的博士后培训生和4-5年的博士前培训生。NTCR 研究员们充分利用了NCI指定的西德尼·金梅尔的研究和临床资源 综合癌症中心，路德威克癌症遗传学和治疗中心，太阳 戈德曼胰腺癌中心，体内细胞和分子成像中心，以及 最近成立的约翰霍普金斯大学独特的教育资源和实验设施 纳米生物技术研究所（INBT），以前是癌症纳米技术中心的所在地 卓越（CCNE）和目前的物理科学肿瘤学中心（PSOC）。

Project Summary The interface between nanotechnology and medicine is a new frontier for scientific exploration and for the creation of new and improved diagnostic and therapeutic tools to detect, treat, cure, and prevent human diseases. We propose to create an integrated predoctoral and postdoctoral training program in nanotechnology for cancer research (NTCR) that is positioned at this interface. It is based on two parent R25 and T32 training grants in the same area. This program will establish a unique national resource with interdisciplinary and synergistic programs in fundamental research in cancer biology, industrial collaboration, and translational research in cancer medicine. This program fosters predoctoral and postdoctoral fellows who are trained across disciplines to lay foundations for technologies that enable an inside-view of cancer cell functions as opposed to the limited black-box input-output techniques currently used, introduce new modalities for molecular imaging, develop new high-throughput diagnostic tools, and engineer novel drug/antibody/siRNA viral and non-viral delivery systems to treat human cancers. NTCR fellows develop novel cancer diagnostics to evaluate each individual patient's prognosis and optimal treatment, based upon the patients' genetic and epigenetic markers and disease phenotype and therapeutics that are selected and optimized for each individual patient. NTCR trainees take one of three core courses depending on their background, as well as a lab course in cancer nanobiotechnology. They participate in a journal club and a dedicated annual symposium, as well as clinical conferences and tumor boards. The NTCR program will recruit outstanding trainees every year with MD and/or PhD degrees and diverse backgrounds in either biochemistry, physics, molecular/cellular/cancer biology, or an engineering/physics discipline for a steady state number of 2 postdoctoral and 6 predoctoral fellows. The NTCR program lasts 3 years for postdoctoral trainees and 4-5 years for predoctoral trainees. NTCR fellows take advantage of research and clinical resources at the NCI-designated Sidney Kimmel Comprehensive Cancer Center, the Ludwick Center for Cancer Genetics and Therapeutics, The Sol Goldman Pancreatic Cancer Center, and the In Vivo Cellular and Molecular Imaging Center, as well as the unique educational resources and experimental facilities of the recently established Johns Hopkins Institute for NanoBioTechnology (INBT), which previously housed the center for cancer nanotechnology excellence (CCNE) and currently the physical sciences-oncology center (PSOC).